EMD-25822
Sphingosine-1-phosphate receptor 1-Gi complex bound to S1P
EMD-25822
Single-particle3.0 Å
Deposition: 30/12/2021Map released: 09/02/2022
Last modified: 09/10/2024
Sample Organism:
Bos taurus,
Rattus norvegicus,
Homo sapiens
Sample: complex of Sphingosine-1-phosphate receptor 1 with G-protein and S1P
Fitted models: 7td3 (Avg. Q-score: 0.574)
Deposition Authors: Liu S, Paknejad N
Sample: complex of Sphingosine-1-phosphate receptor 1 with G-protein and S1P
Fitted models: 7td3 (Avg. Q-score: 0.574)
Deposition Authors: Liu S, Paknejad N
Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate.
Liu S,
Paknejad N ,
Zhu L,
Kihara Y,
Ray M,
Chun J ,
Liu W,
Hite RK ,
Huang XY
(2022) Nat Commun , 13 , 731 - 731
,
Zhu L,
Kihara Y,
Ray M,
Chun J ,
Liu W,
Hite RK ,
Huang XY
(2022) Nat Commun , 13 , 731 - 731
Abstract:
Lysophospholipids are bioactive lipids and can signal through G-protein-coupled receptors (GPCRs). The best studied lysophospholipids are lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). The mechanisms of lysophospholipid recognition by an active GPCR, and the activations of lysophospholipid GPCR-G-protein complexes remain unclear. Here we report single-particle cryo-EM structures of human S1P receptor 1 (S1P1) and heterotrimeric Gi complexes formed with bound S1P or the multiple sclerosis (MS) treatment drug Siponimod, as well as human LPA receptor 1 (LPA1) and Gi complexes in the presence of LPA. Our structural and functional data provide insights into how LPA and S1P adopt different conformations to interact with their cognate GPCRs, the selectivity of the homologous lipid GPCRs for S1P versus LPA, and the different activation mechanisms of these GPCRs by LPA and S1P. Our studies also reveal specific optimization strategies to improve the MS-treating S1P1-targeting drugs.
Lysophospholipids are bioactive lipids and can signal through G-protein-coupled receptors (GPCRs). The best studied lysophospholipids are lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). The mechanisms of lysophospholipid recognition by an active GPCR, and the activations of lysophospholipid GPCR-G-protein complexes remain unclear. Here we report single-particle cryo-EM structures of human S1P receptor 1 (S1P1) and heterotrimeric Gi complexes formed with bound S1P or the multiple sclerosis (MS) treatment drug Siponimod, as well as human LPA receptor 1 (LPA1) and Gi complexes in the presence of LPA. Our structural and functional data provide insights into how LPA and S1P adopt different conformations to interact with their cognate GPCRs, the selectivity of the homologous lipid GPCRs for S1P versus LPA, and the different activation mechanisms of these GPCRs by LPA and S1P. Our studies also reveal specific optimization strategies to improve the MS-treating S1P1-targeting drugs.